131 related articles for article (PubMed ID: 10704894)
41. Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state.
Bayomi MA; Abanumay KA; Al-Angary AA
Int J Pharm; 2002 Aug; 243(1-2):107-17. PubMed ID: 12176299
[TBL] [Abstract][Full Text] [Related]
42. Development of doxycycline hyclate suppositories and pharmacokinetic study in rabbits.
Christ AP; Biscaino PT; Lourenço RL; de Souza AB; Zimmermann ES; Adams AIH
Eur J Pharm Sci; 2020 Jan; 142():105141. PubMed ID: 31706017
[TBL] [Abstract][Full Text] [Related]
43. Amorphous solid dispersion studies of camptothecin-cyclodextrin inclusion complexes in PEG 6000.
Fatmi S; Bournine L; Iguer-Ouada M; Lahiani-Skiba M; Bouchal F; Skiba M
Acta Pol Pharm; 2015; 72(1):179-92. PubMed ID: 25850214
[TBL] [Abstract][Full Text] [Related]
44. Water-soluble Complex of Curcumin with Cyclodextrins: Enhanced Physical Properties For Ocular Drug Delivery.
Maria DN; Mishra SR; Wang L; Abd-Elgawad AH; Soliman OA; El-Dahan MS; Jablonski MM
Curr Drug Deliv; 2017 Sep; 14(6):875-886. PubMed ID: 27501714
[TBL] [Abstract][Full Text] [Related]
45. Formulation of cyclodextrin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability.
Desai S; Poddar A; Sawant K
Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():826-34. PubMed ID: 26478377
[TBL] [Abstract][Full Text] [Related]
46. Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique.
Shinde VR; Shelake MR; Shetty SS; Chavan-Patil AB; Pore YV; Late SG
J Pharm Pharmacol; 2008 Sep; 60(9):1121-9. PubMed ID: 18718114
[TBL] [Abstract][Full Text] [Related]
47. Effect of drug solubility on in vitro availability rate from suppositories with polyethylene glycol excipients.
Realdon N; Ragazzi E; Ragazzi E
Pharmazie; 2001 Feb; 56(2):163-7. PubMed ID: 11234347
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-beta-cyclodextrin.
Nie S; Fan X; Peng Y; Yang X; Wang C; Pan W
Arch Pharm Res; 2007 Aug; 30(8):991-1001. PubMed ID: 17879753
[TBL] [Abstract][Full Text] [Related]
49. Effect of 2-hydroxypropyl-beta-cyclodextrin on crystallization and polymorphic transition of nifedipine in solid state.
Hirayama F; Wang Z; Uekama K
Pharm Res; 1994 Dec; 11(12):1766-70. PubMed ID: 7899242
[TBL] [Abstract][Full Text] [Related]
50. Preparation and characterization of intravaginal vardenafil suppositories targeting a complementary treatment to boost in vitro fertilization process.
Gomaa E; Abu Lila AS; Hasan AA; Ghazy FS
Eur J Pharm Sci; 2018 Jan; 111():113-120. PubMed ID: 28964952
[TBL] [Abstract][Full Text] [Related]
51. Chitosan microspheres with hydrocortisone and hydrocortisone-hydroxypropyl-beta-cyclodextrin inclusion complex.
Filipović-Grcić J; Voinovich D; Moneghini M; Becirevic-Lacan M; Magarotto L; Jalsenjak I
Eur J Pharm Sci; 2000 Feb; 9(4):373-9. PubMed ID: 10664477
[TBL] [Abstract][Full Text] [Related]
52. Use of adjuvants for enhancement of rectal absorption of cefoxitin in humans.
Davis SS; Burnham WR; Wilson P; O'Brien J
Antimicrob Agents Chemother; 1985 Aug; 28(2):211-5. PubMed ID: 3834830
[TBL] [Abstract][Full Text] [Related]
53. Influence of surfactants (present in the dissolution media) on the release behaviour of tolbutamide from its inclusion complex with beta-cyclodextrin.
Veiga MD; Ahsan F
Eur J Pharm Sci; 2000 Jan; 9(3):291-9. PubMed ID: 10594387
[TBL] [Abstract][Full Text] [Related]
54. In vitro release of amoxycillin from lipophilic suppositories.
Webster JA; Dowse R; Walker RB
Drug Dev Ind Pharm; 1998 Apr; 24(4):395-9. PubMed ID: 9876601
[TBL] [Abstract][Full Text] [Related]
55. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
[TBL] [Abstract][Full Text] [Related]
56. Suppositories formulation and drug release.
Moes AJ
Boll Chim Farm; 1989 Jan; 128(1):5-12. PubMed ID: 2673303
[TBL] [Abstract][Full Text] [Related]
57. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
Miro A; Quaglia F; Sorrentino U; La Rotonda MI; D'Emmanuele Di Villa Bianca R; Sorrentino R
Eur J Pharm Sci; 2004 Sep; 23(1):57-64. PubMed ID: 15324923
[TBL] [Abstract][Full Text] [Related]
58. An Approach to Enhance Dissolution Rate of Tamoxifen Citrate.
SreeHarsha N; Hiremath JG; Chilukuri S; Aitha RK; Al-Dhubiab BE; Venugopala KN; Alzahrani AM; Meravanige G
Biomed Res Int; 2019; 2019():2161348. PubMed ID: 30800663
[TBL] [Abstract][Full Text] [Related]
59. Availability of oxyphenbutazone from different suppository formulations.
Ibrahim SA; Abd Elbary A; Elsorady H; Abd Elmonem H
Pharmazie; 1980; 35(4):213-6. PubMed ID: 7403242
[TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method.
Fathy M; Sheha M
Pharmazie; 2000 Jul; 55(7):513-7. PubMed ID: 10944779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
